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Summary
 
The most primitive engrafting hematopoietic stem cell has been assumed to have a fixed phe-
notype, with changes in engraftment and renewal potential occurring in a stepwise irreversible
fashion linked with differentiation. Recent work shows that in vitro cytokine stimulation of
murine marrow cells induces cell cycle transit of primitive stem cells, taking 40 h for progres-
sion from G
 
0
 
 to mitosis and 12 h for subsequent doublings. At 48 h of culture, progenitors are
expanded, but stem cell engraftment is markedly diminished. We have investigated whether
this effect on engraftment was an irreversible step or a reversible plastic feature correlated with
cell cycle progression. Long-term engraftment (2 and 6 mo) of male BALB/c marrow cells ex-
posed in vitro to interleukin (IL)-3, IL-6, IL-11, and steel factor was assessed at 2–4-h intervals
of culture over 24–48 h using irradiated female hosts; the engraftment phenotype showed
marked fluctuations over 2–4-h intervals, with engraftment nadirs occurring in late S and early
G
 
2
 
. These data show that early stem cell regulation is cell cycle based, and have critical implica-
tions for strategies for stem cell expansion and engraftment or gene therapy, since position in
cell cycle will determine whether effective engraftment occurs in either setting.
Key words: hematopoietic stem cell • BALB/c mice • cell cycle • competitive engraftment • 
cytokines
D
 
ogma is that the most primitive hematopoietic stem
cell has a fixed phenotype within a hierarchical differ-
entiation system, with changes in engraftment and renewal
potential occurring in a stepwise fashion linked with differ-
entiation (1). In this model, a loss of “stemness” is irrevers-
ible. Several studies have shown differences in the biology
of resting or cycling hematopoietic stem cells (2–4), and
one has discerned differences in long-term engraftment de-
pendent on the phase of cell cycle. This study showed de-
fective long-term engraftment in S/G
 
2
 
/M compared with
that seen in the G
 
1
 
 phase of cell cycle (4). Our previous
studies showed defective engraftment of unseparated mu-
rine marrow cultured in IL-3, IL-6, IL-11, and steel factor
for 48 h (5, 6).
A major question is whether this engraftment defect was
an irreversible differentiation step or a reversible pheno-
typic change tied to phase of cell cycle. Stem cells purified
from BALB/c male marrow by lineage depletion and selec-
tion of cells which stain dimly with Hoechst and rhodamine
were cultured under the same conditions as unseparated
marrow in IL-3, IL-6, IL-11, and steel factor, and their
progress through cell cycle was mapped using tritiated thy-
midine labeling and cell count doublings (7). The first cycle
transit from dormancy through mitosis took 
 
z
 
36–40 h,
with the five subsequent cycles each taking 
 
z
 
12 h. We
wished to study the engraftment phenotype of long-term
renewing hematopoietic stem cells through the first and
into the second cell cycle. Accordingly, we evaluated en-
graftment into lethally irradiated female BALB/c mice of
male BALB/c marrow cultured in IL-3, IL-6, IL-11, and
steel factor at 2- and 4-h intervals from 24 to 48 h and in
some instances further.
 
Materials and Methods
 
Mice.
 
BALB/c male and female mice (Taconic Farms Inc.,
Germantown, NY) and C57BL6 (Ly5.2) and B6SJL (Ly5.1/Ly5.2)
mice (The Jackson Laboratory, Bar Harbor, ME) were main-
tained under virus-free conditions. Mice were purchased at either
16–18 or 18–22 g (age 6–8 wk), were given food and acidified
water ad libitum, and were housed for a minimum of 1 wk before
experimental use. All experiments were approved by the Univer-
sity of Massachusetts Institutional Animal Care and Use Commit-
tee under docket numbers A707 and A729.
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Fluctuating Phenotype of the Cytokine-stimulated Stem Cell
Figure 1. Engraftment of cy-
tokine-treated male BALB/c
cells into irradiated female hosts:
male BALB/c marrow cells cul-
tured in IL-3, IL-6, IL-11, and
steel factor were analyzed at 2–4-h
intervals for their capacity to
competitively engraft into irradi-
ated female BALB/c mice (650–
1,000 cGy) when competed with
equal numbers (based on starting
input) of normal, noncultured
female cells. (A) In one of five
experiments in which marrow
engraftment was assessed 8 wk
after cell infusion, Southern blot
shows PY2-labeled male se-
quence in DNA from female
BALB/c host marrow. Each
band represents marrow from an
individual mouse. Percent en-
graftment is derived from phos-
phorimaging of original blots.
The low-level engraftment seen
at 32 h was significantly different
from levels at 28 h (P 5 0.009) or
0 h (P 5 0.009). Similarly, values
at 44 and 48 h were significantly different from those at 40 and 0 h (P 5 0.007 and 0.01), respectively. (B) One of two experiments in which marrow was
assessed 6 mo after cell infusion. The engraftment level at 28 h was significantly lower than that at 26 h (P 5 0.03) and at 0 h (P 5 0.01), and that seen at
48 h was different from 44 h (P 5 0.09) and 0 h (P 5 0.01).
 
Figure 2.
 
Graphic representation of mean 
 
6
 
 1 SD for the time of first
nadir and mean 
 
6
 
 1 SD for the time of first recovery for male BALB/c
marrow cells cultured in IL-3, IL-6, IL-11, and steel factor, analyzed for
competitive engraftment (competed with equal starting equivalents of
fresh female marrow) in 1,000 cGy–irradiated female hosts, and superim-
posed on cell cycle parameters separately determined for BALB/c lin-
eage–negative rhodamine
 
lo
 
 Hoechst
 
lo
 
 purified stem cells cultured under
identical conditions. Cell cycle parameters were determined by tritiated
thymidine labeling and cell count doublings. (
 
A
 
) Summary of five experi-
ments analyzed 8 wk after cell infusion. (
 
B
 
) Summary of two experiments
analyzed 6 mo after cell infusion.
 
Culture of Normal Murine Marrow with Cytokines.
 
Bone marrow
was flushed from bones of 6–8-wk-old mice in HBSS from two
tibiae and two femurs. Bone marrow cells were cultured in non-
adherent Teflon flasks at densities ranging from 1 to 5 
 
3
 
 10
 
6
 
 nu-
cleated cells/ml (see Table 1) in DMEM low glucose, supple-
mented with 15% heat-inactivated FCS with cytokines as follows:
recombinant mouse (rm) steel factor at 50 ng/ml, rmIL-3 at 50
U/ml, rmIL-6 at 50 U/ml, and recombinant human IL-11 at 50
ng/ml at 37
 
8
 
C in a fully humidified atmosphere of 5% CO
 
2
 
 in air.
Cells were harvested at different times in culture by vigorous pi-
petting with ice-cold PBS. In one experiment, conditions were
altered, and cells were cultured under serum-free conditions with
IL-3, IL-6, IL-11, and steel factor.
 
Competitive Bone Marrow Transplantation (BALB/c Male to Fe-
male).
 
Female mice were exposed to 650–1,000 cGy (the latter
split 500 cGy 2 h apart) and then injected with 50% cytokine-cul-
tured male BALB/c cells (corresponding to the equivalent start-
ing cell culture number) and 50% fresh noncultured female cells.
The percentage of male cells in host marrow, spleen, or thymus
was determined at 8, 15, or 24 wk after transplantation using
Southern blot analysis with a Y chromosome–specific probe
(PY2) as described previously (5, 6). In brief, genomic DNA was
digested with Dra-1, separated by electrophoresis in 0.8% agar,
and transferred to nylon membranes (Zetaprobe; Bio-Rad Labo-
ratories, Richmond, CA): 
 
32
 
P-labeled PY2 was hybridized to the
 
 o
n
 July 15, 2008 
w
w
w
.jem.org
D
ow
nloaded from
 
 Published July 20, 1998
 395
 
Habibian et al. Brief Definitive Report
blots for 18–22 h, and autoradiography was performed using
x-ray film (XRP; Eastman Kodak Co., Rochester, NY). Quanti-
tation was determined on a PhosphorImager (Bio-Rad Laborato-
ries). Percent male chimerism in female hosts was calculated as
the proportion of male signal in transplanted mice to the signal in
male marrow. Signal from normal female marrow DNA was the
negative background and was subtracted from the male signal.
PY2 values were normalized for loading variance by reprobing
with an IL-3 cDNA.
 
Competitive Bone Marrow Transplantation with Congenic C57BL/
6J (Ly5.2) and B6SJL (Ly5.1/Ly5.2) Mice.
 
Cells were harvested
and cultured as described above. B6SJL recipients were exposed
to 1,000 cGy of radiation (500 cGy given 2 h apart) from a
cesium source irradiator (Gammacell 40; Nordion International,
Kanata, Ontario, Canada). After 2 h, the mice were injected intra-
venously with a mixture of 50% cytokine-cultured B6SJL cells
(equivalent to 5 
 
3 
 
10
 
6
 
 starting cells harvested after the appropri-
ate hour of incubation with cytokines) and 50% noncultured
C57BL/6J cells (5 
 
3
 
 10
 
6
 
 cells). Volume for injection was 0.5 ml
per recipient. The percentage of bone marrow cells expressing
Ly5.1 was determined 18 wk after transplant by flow cytometric
analysis. 10
 
6
 
 suspended cells were incubated for 25 min with
anti-CD45.1 FITC-conjugated antibody (PharMingen, San Diego,
CA) at a total volume per tube of 0.2 ml (0.12 
 
m
 
g/ml in HBSS
 
1
 
1% FCS) at 4
 
8
 
C. The supernatant was aspirated, and cells were
washed twice with cold HBSS and preserved with 2% para-
formaldehyde. The cells were subsequently analyzed with a fluo-
rescence-activated cell sorter (MoFlo; Cytomation, Inc., Fort
Collins, CO).
 
Results and Discussion
 
Cultured male cells were competed with noncultured fe-
male marrow cells (harvested separately for each time
point) in irradiated female hosts, and engraftment of the
male cells in marrow was evaluated at 8 wk or 6 mo after
marrow infusion (Fig. 1, 
 
A
 
 and 
 
B
 
, and Tables 1 and 2).
These studies showed a loss of engraftment over the 28–
36-h interval, a later restoration of engraftment, and a sub-
sequent loss of engraftment again at 44–48 h. A total of five
experiments was carried out evaluating cultured cells and
analyzing engraftment at 8 wk after infusion and two sepa-
rate experiments for the analysis at 6 mo. Tables 1 and 2
present the actual engraftment percentages seen in individ-
ual experiments, and Fig. 2 illustrates the mean time of first
nadir and time of first recovery superimposed on the previ-
ously ascertained cell cycle status of purified cells from
these populations and analyzed at 8 wk. The first nadir oc-
curred on average with cells cultured for 33.2 h, with a
range within 1 SD of 30.2–36.2 h. The first nadir fell
within the late S/G
 
2
 
 phase as determined from previous ex-
periments (Fig. 2). The first nadir compared with 0 h
 
Table 1.
 
Mean Percent Engraftment of Cytokine (IL-3, IL-6, IL-11, and Steel Factor)–treated BALB/c Marrow Cells 8 wk after
Cell Infusion
 
Time in
cytokine
culture
Percent engraftment
Total no. of
mice analyzedExp. 1 Exp. 2 Exp. 3 Exp. 4 Exp. 5
 
h
 
6
 
 SD
 
0 31 
 
6
 
 7 36 
 
6
 
 9 45 
 
6
 
 14 43 
 
6
 
 11 45 
 
6
 
 13 20
24 37 
 
6
 
 11 79 
 
6
 
 11 50 
 
6
 
 25 71 
 
6
 
 21 31 
 
6
 
 9 23
26 32 
 
6
 
 14 40 
 
6
 
 21 39 
 
6
 
 2 12
28 43 
 
6
 
 21 28 
 
6
 
 5 18 
 
6
 
 7 24 
 
6
 
 8 39 
 
6
 
 2 21
30 28 
 
6
 
 19 24 
 
6
 
 9 32 
 
6
 
 11 12
32 7 
 
6
 
 2 32 
 
6
 
 8 72 
 
6
 
 22 33 
 
6
 
 10 22 
 
6
 
 4 22
34 40 
 
6
 
 26 19 
 
6
 
 5 9 
 
6
 
 4 13
36 35 
 
6
 
 10 4 
 
6
 
 1 18 
 
6
 
 9 14 
 
6
 
 2 31 
 
6
 
 14 22
38 29 
 
6
 
 4 4
40 36 
 
6
 
 13 47 
 
6
 
 13 26 
 
6
 
 4 15 
 
6
 
 8 28 
 
6
 
 12 20
42 42 
 
6
 
 4 2
44 1 
 
6
 
 1 20 
 
6
 
 5 59 
 
6 22 17 6 7 18
46 14 6 7 5
48 0.2 6 0.4 3 6 2 27 6 11 37 6 2 33 6 7 20
54 0 6 0 4
60 19 6 7 5
Host mice were exposed to 650 cGy whole body irradiation in experiment (Exp.) 1. In all other experiments, host mice received 1,000 cGy whole
body irradiation. The cell concentration in flask culture was 106 cells/ml. In experiments 1 and 2, 106 female BALB/c cells were competed with 106
noncultured or cultured male BALB/c cells, whereas in experiments 3, 4, and 5, 5 3 106 female BALB/c cells competed against 5 3 106 male BALB/c
cells.
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showed a significant decrease (Wilcoxon’s rank sum test,
P ,0.001). Similarly, the first recovery from nadir, which
occurred on average at 39.6 h, was significant (P ,0.001)
compared with the first nadir value. There was a secondary
nadir seen at the 44–48-h range (P ,0.001). In one exper-
iment, there was a second late recovery seen at 60 h. In
four of five experiments at 8 wk (Table 1), recovery values
after the first nadir exceeded the time 0 value, whereas in
the fifth experiment, the recovery value was .90% of the
0-h value.
Similar results were obtained in the 6-mo experiments
(Fig. 1 B, and Table 2): the mean first nadir occurred at 32 h
of culture (P 5 0.001) compared with 0 h and the first re-
covery at a mean of 42 h (P 5 0.001 compared with first
nadir). In one experiment using the Ly5.1/Ly5.2 transplant
model and assessing engraftment at 15 wk, there was a na-
dir, recovery, nadir, recovery pattern, albeit with some-
what different kinetics (Table 2).
Spleen engraftment was analyzed from BALB/c marrow
cells cultured for 32 or 40 h and compared with input: na-
dir (32 h) and recovery (40 h) values paralleled those seen
with marrow, both at 8 and 24 wk after transplantation
(data not shown), indicating the multilineage nature of en-
graftment from cytokine-cultured cells.
A striking aspect of these studies was the dramatic shifts
in engraftment occurring over 2–4-h time intervals. An al-
teration in engraftment was felt to be biologically signifi-
cant if it represented a relative difference more than two
times the coefficient of variation (SD divided by the mean).
Considering the experiments presented in Tables 1 and 2
(8, 15, and 24 wk after cell infusion), a total of 16 and 8
significant alterations in engraftment were observed at
2- and 4-h intervals, respectively.
Cells cultured under different conditions also evidenced
these engraftment shifts during cytokine-stimulated culture.
When cells were cultured serum-free with IL-3, IL-6, IL-
11, and steel factor, there was a drop in engraftment at 24 h,
but thereafter the same type of fluctuations was seen with
time in culture (Fig. 3), along with a late recovery at 56
and 80 h.
Previous data have indicated an expansion of progenitor
cells in this cytokine combination (5, 6), and other studies
have shown progressive expansions of surrogate progenitor
stem cells in cytokine-stimulated cultures (8, 9). However,
the present data indicate that at least during the first several
Table 2. Mean Percent Engraftment of Cytokine (IL-3, IL-6, 
IL-11, and Steel Factor)–treated Murine Cells 15–24 wk after
Cell Infusion
Time in
cytokine
culture
Percent engraftment
Total no.
of mice
analyzed
Cultured male versus
female BALB/c
Cultured B6SJL
versus C57BL/6
Exp. 1 Exp. 2 Exp. 3
h 6 SD
0 41 6 18 77 6 18 76 6 10 13
24 27 6 16 58 6 14 59 6 18 14
26 37 6 18 26 6 20 67 6 9 13
28 23 6 12 6 6 6 65 6 5 15
30 21 6 18 24 6 14 8 6 10 13
32 10 6 5 40 6 7 9
34 14 6 1 57 6 21 36 6 6 12
36 63 6 21 35 6 18 10
38 4 6 7 5
40 65 6 14 11 6 20 9
42 7 6 1 4
44 28 6 12 64 6 27 25 6 20 13
46 34 6 18 5
48 31 6 0 35 6 9 12 6 16 11
In experiments (Exp.) 1 and 2, male BALB/c cells were cultured at 106
cells/ml. Female BALB/c mice were exposed to 1,000 cGy whole body
irradiation and injected with a mixture of 5 3 106 noncultured female
BALB/c cells and 5 3 106 fresh or noncultured male BALB/c cells, and
engraftment was analyzed at 24 wk. B6SJL cells were cultured at 106
cells/ml, and 5 3 106 cells were competed in 1,000 cGy–irradiated fe-
male mice against 5 3 106 noncultured female C57BL/6 cells. Engraft-
ment was determined by FACS Ò  analysis of Ly5.1-positive cells using
anti-Ly5.1 (CD45.1) FITC-labeled mAb at 15 wk after cell infusion.
Figure 3. Engraftment of BALB/c marrow cells cultured for 80 h un-
der serum-free condition at 3.6 3 106 cells/ml with IL-3, IL-6, IL-11,
and steel factor and analyzed 8 wk after transplantation. 106 cultured male
BALB/c cells in cytokines were competed against 106 noncultured female
cells. Southern blots show PY2-labeled male sequence in DNA from fe-
male BALB/c host marrow. Analysis is as described in the legend to Fig.
1, A and B. The low levels of engraftment seen at 28 and 32 h were sig-
nificantly different from levels at 24 h (P 5 0.005 for both) and 0 h (P 5
0.005 for both). Similarly, values at 48 h were significantly different from
those at 40 h (P 5 0.008) and 0 h (P 5 0.008).
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cell cycles, there are dramatic fluctuations in engraftment
phenotype, which are reversible and thus presumably not
tied to irreversible differentiation steps.
The mechanism underlying this phenotypic engraftment
plasticity may relate to alterations in stem cell “stickiness”
and “trafficking.” Separate studies have shown marked
fluctuations of adhesion protein and mRNA levels at dif-
ferent points in cell cycle (10). The integrin pathways are
complicated, and homing via these pathways probably rep-
resents a multistep process. Other possible mechanisms
could relate to differential sensitivity to transplantation-
induced apoptosis at certain points in the cell cycle, or to
altered responsiveness of transplanted cells at certain points
in cycle to host proliferation and differentiation signaling.
These data demonstrate dramatically different outcomes
with stem cell engraftment based on the precise time in cell
cycle at which the cells are infused. Several gene therapy
approaches with retroviral vectors use in vitro cytokine
stimulation to induce cycling of hematopoietic stem cells to
facilitate incorporation of the vectors into the host genome
(11–13). Clearly, the end results of such approaches with
infusion of gene-transfected stem cells will depend on
whether the hematopoietic stem cells are in an appropriate
state to facilitate engraftment, i.e., presumably G1, or in a
state where engraftment is markedly diminished, i.e., late
S/G2. Similarly a relatively large number of investigators
have developed approaches to expand both human (14–17)
and murine (8, 9) hematopoietic stem cells. These ap-
proaches usually use in vitro cytokine stimulation of he-
matopoietic stem cell populations with subsequent engraft-
ment. Our studies show that a knowledge of the cell cycle
status of these cells will be critical to ensure adequate clini-
cal results with expanded stem cells.
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